WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
ProgenaCare to commercialize coactiv+™ Antimicrobial Wound Gel in the U.S. wound care marketWINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) --...
SCOTTSDALE, Ariz., April 20, 2023 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care...
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 –...
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA...
MISSISSAUGA, Ontario, April 20, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator,...
CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on...
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
LEXINGTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that...
SaaS Solution Delivers up to 93% First-Pass Yield and Prevents Revenue Leakage While Improving Cash Flow by up to 15%BOWIE,...
Expands high-touch, one-on-one approach to all patients in New York including MedicaidEAST RUTHERFORD, N.J., April 19, 2023 (GLOBE NEWSWIRE) --...
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
Addition of new therapeutic expert reflects company’s commitment to drug development in hematologyDURHAM, N.C., April 19, 2023 (GLOBE NEWSWIRE) --...
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model...
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at...
Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6...
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
-- The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population -- -- First-in-human clinical trial...